2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19591
    Fluazacort 19888-56-3 98%
    Fluazacort (L-6400), oxazolino corticosteroid, is a Glucocorticoid Receptor (GR) modulator. Fluazacort can be used for the research of inflammation, immunology and metabolic disease.
    Fluazacort
  • HY-19606
    Cytogenin 132971-59-6 98%
    Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model.
    Cytogenin
  • HY-19656
    HMR1426 262376-75-0 98%
    HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research.
    HMR1426
  • HY-19848
    Cevoglitazar 839673-52-8
    Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research.
    Cevoglitazar
  • HY-19852
    KRP-105 876145-69-6 98%
    KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia.
    KRP-105
  • HY-19861
    SMP-028 914389-14-3 98%
    SMP-028 is an inhibitor of neutral cholesterol esterase (CEase), with an IC50 of 1.01 μM.
    SMP-028
  • HY-19942
    TD-5471 530084-87-8 98%
    TD-5471 is a potent and selective full agonist of the human β2-adrenoceptor.
    TD-5471
  • HY-21586
    7-Methyl-guanosine-5'-triphosphate disodium 104809-18-9 98%
    7-Methyl-guanosine-5'-triphosphate (m7GTP) disodium is a guanosine 5'-phosphate. 7-Methyl-guanosine-5'-triphosphate disodium phosphorothioate analog is a potent cap-dependent translation inhibitor.
    7-Methyl-guanosine-5'-triphosphate disodium
  • HY-29160
    4-Hydroxyisophorone 14203-59-9
    4-Hydroxyisophorone is a derivative of Abscisic acid (HY-100560). 4-Hydroxyisophorone a weak inhibitory effect on plant growth.
    4-Hydroxyisophorone
  • HY-29383
    1,2-Dihydroxy-5-(methylthio)-1-penten-3-one 151169-51-6
    1,2-Dihydroxy-5-(methylthio)-1-penten-3-one is a nucleoside metabolite.
    1,2-Dihydroxy-5-(methylthio)-1-penten-3-one
  • HY-34235
    2-Methyl-1-naphthol 7469-77-4 99.61%
    2-Methyl-1-naphthol is a key precursor in the synthesis of Vitamin K3. 2-Methyl-1-naphthol is can be used for the research of Vitamin K Deficiency.
    2-Methyl-1-naphthol
  • HY-34603
    1-Methyl-1H-pyrazole-3-carboxylic acid 25016-20-0
    1-Methyl-1H-pyrazole-3-carboxylic acid is an intermediate. 1-Methyl-1H-pyrazole-3-carboxylic acid can be used in the synthesis of Compound 91 (SCD1 and SCD5 inhibitor). 1-Methyl-1H-pyrazole-3-carboxylic acid can used in the research of metabolic disorders.
    1-Methyl-1H-pyrazole-3-carboxylic acid
  • HY-45131
    Cholesterol absorption inhibitor 1 190595-65-4 98.66%
    Cholesterol absorption inhibitor 1 (compound 21) is a cholesterol absorption inhibitor that reduces liver cholesteryl ester.
    Cholesterol absorption inhibitor 1
  • HY-78096
    O-Deshydroxyethyl bosentan 174227-14-6 98%
    O-Deshydroxyethyl bosentan is a metabolite of Bosentan (HY-A0013), which is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors.
    O-Deshydroxyethyl bosentan
  • HY-A0179
    Paramethasone 53-33-8 98%
    Paramethasone is an orally active long-acting glucocorticoid. Paramethasone directly inhibits testicular aromatase, thereby reducing the synthesis of estradiol. Paramethasone suppresses the basal and midcycle luteinizing hormone surges in female animals and blocks estrogen synthesis. Paramethasone also decreases circulating levels of dihydrotestosterone, androstenedione and estradiol in male animals. Paramethasone inhibits cartilage degeneration and alleviates joint pathological damage in osteoarthritis models. Paramethasone can be used in research related to osteoarthritis and endocrinology.
    Paramethasone
  • HY-A0287
    Clomiphene 911-45-5 98%
    Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) is an orally active ovulation-inducing agent. Clomiphene binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene ameliorates memory impairment in PCOS models. Clomiphene mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer.
    Clomiphene
  • HY-B0305
    Roxatidine acetate 78628-28-1 98%
    Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity.
    Roxatidine acetate
  • HY-B1416
    Efaroxan 89197-32-0 98%
    Efaroxan is a potent, selective and orally active α2-adrenoceptor antagonist, with antidiabetic activity. Efaroxan is a selective I1-Imidazoline receptor antagonist. Efaroxan can be used for the research of cardiovascular disease.
    Efaroxan
  • HY-B1613
    Clebopride 55905-53-8 98%
    Clebopride is an orally active dopamine Receptor antagonist. Clebopride acts on dopamine D2 receptors and has antiemetic and prokinetic effects. Clebopride can be used in the study of functional gastrointestinal disorders.
    Clebopride
  • HY-B1617
    Zuclomiphene 15690-55-8 98%
    Zuclomiphene is a cis isomer of Clomiphene citrate (HY-B0463). Zuclomiphene is orally active and has an antiestrogenic effect. Zuclomiphene can reduce cholesterol levels. Zuclomiphene can be for the researches of endocrinology and metabolic disease.
    Zuclomiphene
Cat. No. Product Name / Synonyms Application Reactivity